Clinical Trials Directory

Trials / Completed

CompletedNCT00002595

Toremifene in Treating Patients With Desmoid Tumors

PHASE II STUDY OF THE SAFETY AND EFFICACY OF TOREMIFENE IN THE THERAPY OF DESMOID TUMORS

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
72 (estimated)
Sponsor
Advocate Lutheran General Hospital · Academic / Other
Sex
All
Age
16 Years
Healthy volunteers
Not accepted

Summary

RATIONALE: Estrogen can stimulate the growth of cancer cells. Hormone therapy using toremifene may fight the growth of desmoid tumors by reducing the production of estrogen. PURPOSE: Phase II trial to study the effectiveness of toremifene in treating patients with desmoid tumors.

Detailed description

OBJECTIVES: I. Determine the efficacy of toremifene in terms of tumor response rate and symptom relief in patients with desmoid tumors. II. Determine the safety of this regimen in these patients. III. Determine the quality of life of patients treated with this regimen. OUTLINE: Patients are stratified by gender. Patients receive oral toremifene daily until complete or maximal response in the absence of disease progression or unacceptable toxicity. Patients achieving maximal response undergo complete resection of all lesions, if feasible. Nonsurgical candidates with severe or life-threatening disease not achieving partial or complete response or symptom relief at 12 months may continue on toremifene at the discretion of the study chairperson. Patients with stable disease who do not undergo surgery may continue on toremifene for a maximum of 12 months at the discretion of the treating physician. Patients who continue to experience symptom relief at 12 months may continue on toremifene at the discretion of the study chairperson. Quality of life is assessed at baseline and at 2 and 6 months. Patients are followed every 8 weeks for 4 years and then annually thereafter. PROJECTED ACCRUAL: A total of 24-72 (12-36 per stratum) will be accrued for this study.

Conditions

Interventions

TypeNameDescription
DRUGtoremifene
PROCEDUREconventional surgery

Timeline

Start date
1991-07-01
Primary completion
2003-05-01
Completion
2010-09-01
First posted
2004-04-22
Last updated
2013-07-10

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00002595. Inclusion in this directory is not an endorsement.